CD274 and neoplasm: Immune-based therapies can take advantage of potentially synergistic interactions between agents such as anti-PD-L1 and radiation-induced anti-tumor immune effects.29,34 Moreover, these systemic interactions could augment any abscopal effects and improve disease-specific survival.